PROJECT REPORT ON

TO ASSESS THE USAGE OF ALLOPATHIC AND AYURVEDIC PRODUCTS BY DIFFERENT DOCTORS

(THE VEIWS OF DOCTORS)
SUBMITTED TO:
SUBMITTED BY:
Mr. J.S.SAINI
SENIOR MANAGER MARKETING
LOVEKESH SARDA
REGD.NO:10806768 LOVELY PROFESSIONAL UNIVERSITY
IndSwift.ltd

TABLE OF CONTENTS
ACKNOWLEDGEMENT PREFACE
EXECUTIVE SUMMARY
CHAPTER 1.
Introduction to study

Review of literature CHAPTER 2

Company profile

CHAPTER 3
Objectives of the study
Research methodology Research design
Sample design and s
ize Sources of data
Scope of the study CHAPTER 4 Data analysis CHAPTER 5
Finding
s Recommendations
Conclusion Questionnaire
Bibliography

PREFACE
Our Institute has made a sincere effort in providing linkage between industry an
d students. Industrial Training is a platform for a student to supplement his th
eoretical knowledge with practical knowledge. The main purpose of Industrial Tra
ining is to get an exposure in industrial environment, which is not possible in
classroom. The training also tells about the limitation of the knowledge of a pe
rson and helps in clearing the concept easily and effectively. The Industrial tr
aining also made me aware of the importance of discipline, punctuality, teamwork
, sense of responsibility . I undertook my project at IndSwift. Ltd. It is a pio
neer organization in manufacturing and supplying allopathic and ayurvedic drugs
in India and to other countries. The training is definitely going to play an imp
ortant role in developing an aptitude for handwork and self confidence for my su
ccessful future.

ACKNOWLEDGMENT
I am thankful to Mr. S.R.MEHTA who is chairman of the company for permitting me
to complete the project in such a reputed company in the market. I would like to
thank Mr. J.S. SAINI the project guide of industry who guide me how to work on
project report. Helped me to choose the project topic and provide information ti
me to time. I express an extreme sense of gratitude to Dr. JASDEEP DHAMI for the
ir suggestions to me when I am needed. I wish to thanks the entire staff & worke
rs of IndSwift. LTD for their suggestions, guidance & co-operation.

EXECUTIVE SUMMARY
PROJECT TITLE: EVALUATION STUDY TO ASSESS THE USAGE OF ALLOPATHIC AND
AYURVEDIC PRODUCTS IN VEIWS OF DOCTORS.
My project is to assess the usage of allopathic and ayurvedic by the doctors. In
this survey I found very zigzag results. Every doctors have different type of w
ay to heal particulars . Some doctors used their basic practices and some with c
ombination therapy. This fact is totally depending on the regions. Interior area
gives you the results for combination therapy, where developed cities provides
the basic one . My project sampling was carried out in interior area of Hamirpur
(H.P). and Chandigarh . Sample size is 20 ayush doctors and 20 allopathic docto
rs. Health care in Hamirpur and Chandigarh is provided by allopathic and traditi
onal health care . These health care services are most effective if they are com
patible with the needs and aspiration of the people . Allopathic and ayurveda se
rvices in Hamirpur and Chandigarh provided by private, compounders and health ce
nters of govt. But the difference in Chandigarh and hamirpur is, in hamirpur due
to socio-cultural and economics reasons a modern health care systems not widely
prevalent. So they more depends on traditional systems of medicines. Even in de
veloped country or world the use of complementary and alternative medicines has
been steadily increasing in previous decades. The basic requirement for allopath
ic doctors is allopathy. But ayurveda doctors oftenly use the allopathic medicin
es on the customer preferences, first aid, in emergency. As large no: of acciden
t occurs in daily life so besides giving ayurvedic medicines to patient these ay
urveda doctors often have to take up the other modes of medication. Hence this p
oint accepts the allopathic treatment is life saving drug in emergency. But for
long term, safe, non toxic is herbal . This whole treatment is based on the dise
ases. When a patient is diagnosed with the medical problem, the allopathic docto
rs in audience with cunsultant of traditional therapy

decides on the treatment procedure. If the ailment is critical, the patient is s

ent to the allopathic doctors . For instance, if a person is suffering from asth
ma or bronchial pain or diabetes and is in early stages of diseases, allopathic
medicines along with ayurveda can be suggested. In the way, modern medicines wor
ks to reach the disease while traditional one cure and cleanse the body. To comp
arison both system is impossible. But market survey has still weightage of allop
athic. But ayurveda is on ignition stage.
OBJECTIVE OF THE STUDY:
1> To assess the usage of allopathic or ayurveda system by the doctors. 2> To st
udy the preferences of the systems by the doctors taking the reasons as side eff
ects, time duration, safety. 3> To study the availability the medicines in clini
c or nearby retailers. 4> To know diversifying allopathic to ayurveda by industr
ies is right step or not. 5> To study the order of preferences by the doctors to
wards the different medical professionals.
SCOPE OF THE STUDY:
The scope of study means the subject matter to be researched in the study . It d
efines the overall rationale of the study by explaining the geographically area
of the study along with type of the data. In order to accomplish the objectives
of the project . Survey conducted in Himachal Pradesh and Chandigarh to fill the
questionnaire by the doctors which designed for the purpose of the survey . On
the basis of data collected I analysis the result of the project .
RESEARCH METHODOLOGY
In order to gets information by various reasons the research methodology is as f
ollows: DATA COLLECTION: Adequate and authentic data is the foundation stone for
an analysis. It is very necessary that the data should be adequate and relevant
so that the analysis which we derive from that data is exact. So data collectio
n requires due attention and care. In order to get the required basic informatio
n

about the usage of medical system by doctors and for what disease . I relied on
both primary data and secondary data.
PRIMARY DATA: Regular visit to the organization i.e.IndSwift Ltd. In Chandigarh
and after regular visit to market and meetings with doctors was made to obtain t
he required information and learn about the market and organisation how it works
. Interviews with the management officials and staff of the organization to get
latest information.
SECONDARY DATA: Books, Magazines, Articles from internet etc. constitute the sec
ondary sources of information for the project report.
SAMPLING PLAN: Universe : The population of study consists of hamirpur and chand
igarh. Sample Size : Sample Sizes 40 respondants. 20 doctors of ayurveda and 20
from allopathic . Sampling Technique : I have used technique of convenience samp
ling. Geographical scope: Hamirpur (h.p) and Chandigarh . . Tool for data analys
is : Percentage method for getting results. doctors and retailers (pharmacy shop
s) I
FINDINGS:
In my market survey I found weightage towards the allopathic products . 35% of a
llopathy doctors use ayurveda medicine in prescription but in case of ayurvedic
doctors 80% of them , they are using allopathic medicine in prescription. I also
find that the combination therapy made by doctors doing great job in healing th
e disease like coronary heart disease , cancer and many more chronicle diseases.
upcoming one. As allopathic is first preference by the doctors but ayurveda is

RECOMMENDATION:
According to findings that in current scenario doctors and patient move towards
the ayurveda but allopathic still rules. I would like to recommend IndSwift 1. D
octors have yet to find a solution for conditions like cancer pain and chronic p
ancreatitis in complementary therapies where modern interventional pain procedur
es are very effective. So herbal drugs use in cancer and heart disease is going
to be popular for the doctors. This finding helps IndSwift to capture market by
manufacturing of anti cancer herbal drug. 2. My findings helps IndSwift that it
should work on herbal medicines but along with allopathic. 3. In future company
get benefit if they prepare combination therapy medicines with no side effect an
d try to be 100% cure guarantee.

CHAPTER- 1 INTRODUCTION TO SUBJECT: AYURVEDA

Ayurveda (Devangar:
, the 'science of life') is a system of traditional medicine nati
to India, and practiced in other parts of the world as a form of alternative med
icine. In Sanskrit, the word Ayurveda comprises the words yus, meaning 'life' and
veda meaning knowledge . Evolving throughout its history, Ayurveda remains an i
nfluential system of medicine in South Asia. The earliest literature of Ayurveda
appeared during the Vedic period in India. The Sushruta Samhita and the Charaka
Samhita were influential works on traditional medicine during this era. Ayurved
ic practitioners also claim to have identified a number of medicinal preparation
s and surgical procedures for curing various ailments and diseases. As per India
n heritage and science "Ayurveda" is a Upa Veda or anexture of four main vedas(K
nowledge Systems). the famous treaties of Ayurveda, "Charaka Samhita" by sage "C
harakan", details the prevention and treatment of disease and "Sushruta Samhita"
of Sage "Sushruta" deals Ayurvedic Surgical procedures. In Ayurvedic system, Pr
evention of all types of

disease have prominent place than treatment, including restructuring of life sty
le to align with the course of nature and four seasons, which will guarantee com
plete wellness. Ayurveda is considered to be a form of complementary and alterna
tive medicine (CAM) within the western world, where several of its methodssuch as
herbs, massage, and Yoga as exercise or alternative medicineare applied on their
own as a form of CAM treatment. Ayurveda believes in five great Elements (Devang
ar:
; earth, water, fire, air and space)-to compose the Universe, including the human
dy.Chyle, blood, flesh, fat, bone, marrow, and semen are believed to be the seve
n primary constituent elements (Devangar:
) of the body.Ayurveda stresses a balance
ree substances: wind/spirit/air, phlegm, and bile, each representing divine forc
es. According to Ayurveda, these three regulatory principles--Doshas (Devangar:
)vat
nd/spirit/air), pitta (bile) and kapha (phlegm)are important. Traditional beliefs
hold that humans possess a unique constellation of Doshas. In Ayurveda, the hum
an body perceives attributes of experiences as 20 Guna (Devangar:
, meaning qualities
).Surgery and surgical instruments are employed. It is believed that building a
healthy metabolic system, attaining good digestion, and proper excretion leads t
o vitality. Ayurveda also focuses on exercise, yoga, meditation, and massage.Thu
s, body, mind, and spirit/consciousness need to be addressed both individually a
nd in unison for health to ensue. The concept of Panchakarma (Devangar:
) is believe
eliminate toxic elements from the body. Eight disciplines of Ayurveda treatment,
called Ashtanga (Devangar:
), are given below:
Surgery (Shalya-chikitsa). Trea
f diseases above the clavicle (Salakyam). Internal medicine (Kaaya-chikitsa). De
monic possession (Bhuta vidya): Ayurveda believes in demonic intervention andas a
form of traditional medicineidentifies a number of ways to counter the supposed e
ffect of these interferences.[13] Bhuta vidya has been called psychiatry.
Pediat
rics (Kaumarabhrtyam). Toxicology (Agadatantram). Prevention and building immuni
ty (rasayanam). Aphrodisiacs (Vajikaranam). Ayurveda gained recognition in the W
estern world as

medical scholars, notably , Frank John Ninivaggi MD of Yale University School of

Medicine, researched and outlined its various postulates in one major textbook
form suitable to Western academic science. In the United States of America, the
NIH NCCAM expends some of its $123 million budget on Ayurvedic medicine research
. In India the government became involved in traditional drug production when th
e Central Drug Research Institute patented two new drugs from ancient Ayurvedic
formulas. One, a mixture of black pepper, long pepper, and ginger, allows for th
e dosage of the antibiotic rifampicin to be halved in the treatment of tuberculo
sis and other mycobacterial infections. The other is a memory tonic produced fro
m the traditional plant called brahmi. Overseas patenting of turmeric and produc
ts of the neem tree caused controversy in India and other nations. In August the
U.S. Patent and Trademark Office canceled a U.S. patent on the wound-healing pr
operties of turmeric when the Indian government proved that records had existed
for this use for centuries.

ALLOPATHY
Allopathic medicine and allopathy (from Greek ,
s,
ther, different + , th
s,
are terms c
ined by Samue Hahnemann, the f
under
f h
me
athy. It meant "
the
r than the disease" and it was intended, am
ng
ther things, t

int
ut h
w tr
aditi
na d
ct
rs used meth
ds that had n
thing t
d
with the symt
ms created
with the disease, which meant that these meth
ds were harmfu t
the atients. O
rigina y intended as a characterizati
n
f standard medicine in the ear y 19th
century, these terms were rejected by mainstream hysicians and quick y acquired
negative
vert
nes. During the 19th century it was used wide y am
ng irregu ar
d
ct
rs as a ej
rative term f
r regu ar d
ct
rs.In the United States the term "
a
athic" has been used by ers
ns n
t re ated t
h
me
athy, but it has never
been acceted by the medica estab ishment, and is n
t a abe that such indivi
dua s a y t
themse ves. In the United States, a
athic medicine can s
metim
es refer t
the medica training that eads t
the degree D
ct
r
f Medicine rat
her than the degree D
ct
r
f Oste
athic Medicine, a th
ugh this is unc
mm
n. S
ee c
maris
n
f MD and DO in the United States. Genera y, a
athic medicine
refers t
"the br
ad categ
ry
f medica ractice that is s
metimes ca ed Weste
rn medicine, bi
medicine, scientific

medicine,
r m
dern medicine", with varying degrees
f accetance by medica r

fessi
na s in different
ca es. In articu ar, the terms a
athic medicine an
d a
athy may be used f
r regu ar medicine in a c
ntext
f traditi
na medicin
e such as Ayurveda as we as in a c
ntext
f c
m ementary and a ternative medi
cine such as h
me
athy (see h
me
athy and a
athy). H
wever, many asects
f
traditi
na medicine systems such as Ayurveda
r Traditi
na Chinese medicine a
re themse ves a
athic in that they act by

sing the atient's symt
ms.
SUREY STUDY
A
athy and ayurveda are as different as day and night, and hence the tw
sets

f

sing views. H
wever, if
ne has t
c
mare ayurveda and a
athy
n
ne
 atf
rm, then such c
maris
n might be a tad difficu t. "A
athy treats indi
vidua s as an indeendent hysica entity ike a machine. It is further sub-divi
ded int
vari
us
rgans and systems

ked after by different secia ties. Where
as, ayurveda treats the individua as a wh
e, c
nsidering him t
be a art
f t
he universa wh
e . A 
sitive asect in the wh
e ayurveda vs a
athy issue,
is the fact that, e
 e are n
w
en t
kn
w m
re ab
ut this ancient science.
A s
whi e there might n
t be rejudices
r bias against the same, there are cer
tain misc
nceti
ns, which can
n y be dise ed with kn
w edge and inf
rmati
n
disseminati
n. "There are n
rejudices surr
unding ayurveda. There may be misc

nceti
ns regarding its ractice. If anything, the interest in this system
f me
dicine has been gr
wing raid y b
th in the d
mestic and internati
na market, a
ttesting t
its 
u arity and widesread accetance. My r
ject is t
assess th
e usage
f a
athic and ayurvedic by the d
ct
rs. In this survey I f
und very
zigzag resu ts. Every d
ct
r have different tye
f way t
hea articu ars. S
m
e d
ct
rs used their basic ractices and s
me with c
mbinati
n theray. This fac
t is t
ta y deending
n the regi
ns. Interi
r area gives y
u the resu ts f
r c

mbinati
n theray, where deve
ed cities r
vides the basic
ne. My r
ject sa
m ing was carried
ut in interi
r area
f Hamirur (h.). and Chandigarh . Sam
e size is 20 ayush d
ct
rs and 20 a
athic d
ct
rs. Hea th care in hamirur a
nd Chandigarh is r
vided by

a
athic and traditi
na hea th care . These hea th care services are m
st eff
ective if they are c
matib e with the needs and asirati
n
f the e
 e . A

athic and ayurveda services in Hamirur and Chandigarh r
vided by rivate , c

m
unders and hea th centers
f g
vt. But the difference in Chandigarh and hamir
ur is, in hamirur due t
s
ci
-cu tura and ec
n
mics reas
ns a m
dern hea th
care systems n
t wide y reve ant. S
they m
re deends
n traditi
na systems

f medicines . Even in deve
ed c
untry
r w
r d the use
f c
m ementary and a
ternative medicines has been steadi y increasing in revi
us decades . The basic
requirement f
r a
athic d
ct
rs is a
athy. But ayus d
ct
rs
ften y use t
he a
athic medicines
n the cust
mer references, first aid, in emergency. As
arge n
:
f accident
ccurs in dai y ife s
besides giving ayurvedic medicine
s t
atient these ayush d
ct
rs
ften have t
take u the
ther m
des
f medica
ti
n. Hence this 
int accets the a
athic treatment is ife saving drug in e
mergency. But f
r
ng term , safe , n
n t
xic is herba . This wh
e treatment
is based
n the diseases . When a atient is diagn
sed with the medica r
b em,
the a
athic d
ct
rs in audience with c
nsu tant
f traditi
na theray decid
es
n the treatment r
cedure. If the ai ment is critica , the atient is sent t

the a
athic d
ct
rs. F
r instance , if a ers
n is suffering fr
m asthma
r
br
nchia ain
r diabetes and is in ear y stages
f diseases , a
athic medi
cines a
ng with ayurveda can be suggested . In the way, m
dern medicines w
rks
t
reach the disease whi e traditi
na
ne cure and c eanse the b
dy. T
c
mari
s
n b
th system is im
ssib e. But market survey has sti weightage
f a
ath
ic. But ayurveda is
n igniti
n stage.
LITERATURE AND LITERATURE REIEW
SHANKAR.R.(2001):
A survey
f drug use atterns in western Nea Shankar PR, Kumar P, The
d
re AM,
Partha P, Shen
y N.,Dr.P.Ravi Shankar MD Mr.A.M.The
d
re MSc Deartment
f Phar
mac

gy Deartment
f C
mmunity

MedicineMania C
ege
f Medica Sciences Mania C
ege
f Medica Sciences

P
khara, Nea . P
khara, Nea . Dr.Pawan Kumar MD Dr. Praveen Partha DNB Deartm
ent
f C
mmunity Medicine Deartment
f Medicine Mania C
ege
f Medica Scie
nces Mania Teaching H
sita P
khara, Nea . P
khara, Nea Mr. Nagesh Shen
y
M.Pharm Deartment
f C
mmunity Pharmacy Mania Teaching H
sita P
khara, Nea
. Name
f deartments t
which the w
rk sh
u d be attributed: Deartments
f Ph
armac

gy , C
mmunity medicine AND Interna medicine Mania C
ege
f Medica
Sciences P
khara, Nea . Name and address
f c
rres
nding auth
r: Dr.P.Ravi Sh
ankar , Deartment
f Pharmac

gy , Mania C
ege
f Medica Sciences P.O.B
x
155 , Dee Heights P
khara, Nea . E-mai : mc
ms@m
s.c
m.n athiyi ravi@rediff
mai .c
m Abstract: Backgr
und: In Nea , traditi
na hea th care r
viders have
an im
rtant r
e t
 ay in the r
visi
n
f hea th services. N
n-d
ct
r rescr
ibing
f a
athic medicines is c
mm
n y carried
ut by c
m
unders, hea th ass
istants and
ther ractiti
ners. Se f-treatment in which herba remedies  ay a
arge r
e is a s
c
mm
n. M
st
f the revi
us studies have been carried
ut in
the Kathmandu va ey. As studies in the P
khara va ey are acking the resent
study was carried
ut. Meth
ds: The study was carried
ut in P
khara sub-metr


itan city and the surr
unding vi ages in the m
nth
f Setember 2001 using a s
emi-structured questi
nnaire by the hea th w
rkers
f the c
mmunity medicine de
artment. The attern
f drug use in the receding 6 m
nth eri
d was n
ted. Diff
erences in the r

rti
n
f atients using se f-medicati
n and

c
m ementary medicines acc
rding t
age,  ace
f residence and s
ci
ec
n
mic s

tatus
f fami y were ana ysed by the z test
f r

rti
ns (<0.05). Findings an
d c
nc usi
ns: 112 h
useh
ds were surveyed during the study eri
d. 120 individ
ua s fr
m these h
useh
ds had been rescribed medicati
ns during the study eri

d. There was a t
ta
f 164 enc
unters with the hea th care system. Se f-medica
ti
n was racticed by 39 fami ies during the study eri
d. H
me remedies acc
unt
ed f
r 18.9 %
f the drugs used. 71.6 %
f the res
ndents using rescribed medi
cati
ns had used m
dern medicines. Se f-medicati
n was m
re c
mm
n am
ng rura h

useh
ds. Imr
ving accessibi ity t
medicines, imr
vement
f the g
vernment h
ea th care system and greater integrati
n
f traditi
na and m
dern hea th care
systems are rec
mmended. Keyw
rds: Drugs, medicati
n-statistics. Intr
ducti
n: H
ea th care in Nea is r
vided by b
th a
athic and traditi
na hea th care 
r
viders. Hea th care services are m
st effective if they are c
matib e with th
e needs and asirati
ns
f the e
 e. A
athic services in Nea can be r
vi
ded by rivate ractiti
ners, c
m
unders and the g
vernment hea th centres. C
m

unders are usua y ers
ns with
ut a f
rma medica educati
n wh
have been w

rking under a registered medica ractiti
ner he ing him reare medicines, dre
ssing the atients and d
ing
ther j
bs in the c inic. They usua y start their

wn c inics after gaining a few years exerience. Traditi
na hea th care r
vid
ers are c assified as: a) Faith hea ers: 1) Dhami-Jhankri 2) Ojha 3) Pandit-Lama
-Gubhaju-Pujari and 4) Jy
tishi and b) Medica r
viders: 1) Baidhya-Kabiraj 2)
Jadi-Buti wa a.1 Dhami-jhankris are faith hea ers wh
by beating a drum and ritu
a istic chanting uts the atient int
a trance. Pandit, Lama, gubhaju and ujar
is are the riests
f the different ethnic and re igi
us gr
us
f Nea . Baidhy
as and Kabiraj are ayurvedic ractiti
ners wh
use herbs a
ng with
ther e ixir
s, meta rearati
ns etc. Jadibuti wa as are herba ists wh
use
n y herba re
arati
ns. In Nea due t
hist
rica , s
ci
-cu tura and ec
n
mic reas
ns a m
d
ern hea th care system is n
t wide y reva ent. S
there is an increased deende
nce
n traditi
na systems
f medicine. Even in the deve
ed w
r d the use
f c

m ementary and a ternative medicines (CAM) has Drug-M
nit
ring-meth
ds, N
n-r
escriti
n-theraeutic use, Se f-

been steadi y increasing in the revi
us decade.2,3 In the deve
ed c
untries,
atients referring CAM are genera y fema e,
f a high s
ci
-ec
n
mic c ass and
with a m
re h
istic ar
ach t
ife.4,5 In Nea ab
ut tw
decades ag
studie
e
 e turned t
their Dhami-Jhankris f
r much
f thei
s has f
und that the hi
r hea th care needs.6 H
wever, these studies were main y c
ncentrated ar
und the
Kathmandu va ey and maj
r 
itica and s
ci
-ec
n
mic changes have taken  ac
e in the ast tw
decades. Many new medica c
eges have c
me u a
ver Nea
and the number
f trained d
ct
rs has increased substantia y.7 Previ
us y it w
as f
und that m
st
ca e
 e referred rivate disensaries
wned by s
-ca e
d c
m
unders t
the free hea th services at the g
vernment
erated hea th cent
res.8 Unfami iarity with the medica ers
nne and absence
f medicines were the
reas
ns cited f
r n
t referring the hea th centre. In Kaski district and
ther
se ected districts
f Nea a c
mmunity fund has been set u t
ensure that the
hea th centres are we st
cked with medicines. Se f-treatment
f c
mm
n i nes
ses by ay e
 e is c
mm
n in ec
n
mica y derived c
untries.9,10 C
mm
n reas

ns cited f
r se f-medicati
n are inaccessibi ity
f hea th care faci ities, ec
n

mic c
nstraints and revi
us exerience
f i ness. Since drug-use studies in t
he c
mmunity and fact
rs inf uencing the drug use atterns are acking in P
khar
a va ey the resent study was carried
ut. Meth
ds: The study was carried
ut i
n P
khara sub-metr

itan city, western Nea and the surr
unding vi ages duri
ng the m
nth
f Setember 2001. The res
ndents were interviewed by the hea th w

rkers
f the deartment
f c
mmunity medicine wh
were briefed bef
re hand. A s
emistructured questi
nnaire was used f
r the interviews. The ethnic gr
u,
ccu
ati
n, average m
nth y fami y inc
me, the number
f members in the fami y and th
e address
f the res
ndents were n
ted. The attern
f drug use in the fami ies
in the six m
nth eri
d receding the date
f data c
ecti
n was n
ted. Detai
s ab
ut the atient wh
had used medicines in the revi
us six m
nths, the syste
m
f medicine referred, the ractiti
ner and the s
urce
f medicine was a s
c

ected. Detai s ab
ut the medicines, the atient
utc
me and the ar
ximate ex
enditure
n the medicines were n
ted. If re evant the reas
n f
r referring c
m
 ementary and a ternative medicines(CAM) were a s
n
ted. Res
ndents were aske
d ab
ut any se f-medicati
n eis
des

in their fami y during the receding six m
nths. The reas
n f
r n
t c
nsu ting a
d
ct
r and detai s
f the medicines used f
r se f-medicati
n was c
ected. Dif
ferences in the r

rti
n
f atients using se f-medicati
n and c
m ementary m
edicines acc
rding t
age,  ace
f residence and s
ci
-ec
n
mic status
f fami
y were ana ysed using the z test
f r

rti
ns. A  va ue < 0.05 was taken as s
tatistica y significant. Resu ts: One hundred and twe ve res
ndents were inter
viewed using the questi
nnaire during the study eri
d. Eighty seven
f the 112
h
useh
ds surveyed (77.7 %) were ma e headed. The c
mm
nest ethnic gr
u enc
un
tered in the study was Brahmins 34(30.3 %). Other significant gr
us were Gurung
s 15 (13.4 %) and Chettris 13 (11.6%). Sixty
ne
f the t
ta
f 112 h
useh
ds
were engaged in n
n agricu tura ursuits. Fifty tw
h
useh
ds were midd e c as
s by Nea ese standards with an average m
nth y inc
me between 1000 and 3000 Ne
a ese ruees (13 and 40 US d
ars). Twenty tw
h
useh
ds were 

r with an ave
rage m
nth y inc
me ess than 1000 ruees (13 US d
ars). Maj
rity
f the h
use
h
ds (66.9 %) had ess than 6 members. Eighty h
useh
ds were urban and the res
t were rura . Seventy f
ur h
useh
ds (66 %) had used rescribed medicati
ns dur
ing the study eri
d. One hundred and twenty individua s had been rescribed med
icines during the eri
d. F
rty three
f the t
ta
f 120 individua s wh
had us
ed medicines were aged between 20-30 years. The next c
mm
nest age gr
u was bet
ween the years 40-50. The 120 res
ndents had a t
ta
f 164 enc
unters with the
hea th care system in the 6 m
nth eri
d receding the study. M
dern a
athic
medicines were rescribed in 118 enc
unters. The atients had visited m
re than

ne ractiti
ner f
r an eis
de
f i ness. The d
ct
r and the hea th assistant
were the c
mm
n y visited ractiti
ners and acc
unted f
r 28 % and 27.4 %
f th
e t
ta visits. Twenty eight %
f the visits were t
a CAM ractiti
ner. The med
ica sh
 was the c
mm
nest s
urce
f medicines f
r the res
ndents
f the study
. The medica sh
s s
d drugs b
th
n rescriti
n and a s

n demand fr
m the
res
ndents with
ut a rescriti
n. The medica sh
s genera y s
d a
athic
medicines a
ng with a few CAM remedies. In the 164 enc
unters a t
ta
f 217 dr
ugs were rescribed giving an average
f 1.32 drugs er enc
unter.

Traditi
na medicines c
nstituted 32.2 %
f the t
ta drugs c
nsumed. The c
mm
n
est a
athic medicines c
nsumed were antibi
tics and aracetam
acc
unting f

r 24.3 % and 18 %
f the t
ta drugs rescribed. The ar
ximate fami y exendit
ure
n medicati
ns during the receding six m
nth eri
d was ess than 100 ruee
s (1.25 US d
ars) in 32.9 %
f the cases and m
re than 250 ruees (4 US d
ar
s) in 34 %
f the cases. Se f-medicati
n was racticed by 39 fami ies
f the 112
surveyed in the study. The c
mm
nest drug was aracetam
acc
unting f
r 41.3 %

f the drugs used. Traditi
na h
me remedies acc
unted f
r 18.9 %
f the drugs
used f
r se f-medicati
n. The c
mm
n s
urces
f drugs used were the medica st
r
e and herbs and r

ts fr
m the surr
unding f
rests and a s

btained fr
m the c

urtyards
f the h
uses. Am
ng the 39 fami ies wh
had taken se f-medicati
n and
h
me remedies in the receding 6 m
nth eri
d, 24 fami ies had sent ess than 7
5 Nea ese ruees (1 US d
ar), 12 fami ies had sent between 75 and 225 Nea e
se ruees (1 and 3 US d
ars) whi e 3 fami ies had sent
ver 225 Nea ese rue
es (3 US d
ars). A significant y greater r

rti
n
f individua s ab
ve the a
ge
f 30 years had used c
m ementary medicines c
mared t
th
se ess than
r e
qua t
30 years
f age (z=2.46, <0.05). CAM usage was a s
significant y highe
r am
ng fami ies with an average m
nth y inc
me ess than 1000 ruees (13 US d

ars). The c
mm
nest reas
ns cited f
r using CAM remedies were faith in the rac
titi
ner and ess side effects. The reas
ns cited f
r the use
f m
dern a
ath
ic medicines fr
m ractiti
ners
ther than d
ct
rs were n
n-avai abi ity
r decr
eased accessibi ity
f d
ct
rs
r the d
ct
r was exensive. The reas
ns given f

r se f-medicati
n were sim e i ness, revi
us exerience
f treating a simi ar
i ness and medicina herbs were easi y avai ab e in the c
urtyard
f the h
use
. Discussi
n: The c
mm
nest ethnic gr
u enc
untered in the study were Brahmins
f

wed by Gurungs and Chettris. This c
rres
nds t
the data in the District d
eve
ment r
fi e
f Nea .M
st
f the res
ndents in the study were engaged in
n
n-agricu tura
ccuati
ns and this c
u d be because 80 %
f the res
ndents
were residing in P
khara city.

A t
ta
f 217 drugs were rescribed during the 6 m
nth eri
d which was studied
. This is difficu t t
c
mare with revi
us studies as the 
u ati
n and s
ci

ec
n
mic arameters are different. 71.6 %
f the res
ndents using medicines had
used m
dern medicines. In a revi
us study based
n the meta-ana ysis
f itera
ture m
re than 50 %
f e
 e in Nea had used CAM remedies. The higher use
f
a
athic medicines c
u d be due t

ur study 
u ati
n being m
re urban and t
he ec
n
mic deve
ment indices
f Kaski district being higher than
f m
st
the
r regi
ns in Nea . The res
ndents had visited m
re than
ne ractiti
ner durin
g an eis
de
f i ness. C
mm
n reas
ns cited were the i ness was n
t cured, e
rs
na attenti
n was n
t given by the ractiti
ner and the atient did n
t have
sufficient faith in the ractiti
ner. The res
ndents referred CAM remedies es
ecia y f
r chr
nic i nesses which is simi ar t
the findings in revi
us studi
es.12,13 The d
ct
r and the hea th assistant were the c
mm
n y visited ractiti

ners. D
ct
rs in rivate ractice acc
unted f
r 60.2 %
f the t
ta visits t
d

ct
rs. The uti isati
n
f g
vernment hea th faci ities was
wer than that re
r
ted by revi
us studies in Ethi
ia and Thai and. In a revi
us study in Nea 
rivate ractiti
ners were f
und t
be m
re 
u ar than the g
vernment hea th e
rs
nne The reas
ns cited f
r the reference were the rivate ractiti
ners were

ca e
 e and were m
re accessib e at any time
f the day
r night. A r

r
ti
n
f the res
ndents had visited g
vernment d
ct
rs as rivate atients when
they were d
ing rivate ractice in the evenings. CAM remedies c
ntinue t
be 

u ar b
th as h
me remedies and
n rescriti
n by a CAM ractiti
ner. Herba re
medies as sh
wn in a revi
us study are easi y avai ab e and in Nea kn
w edge

f herba remedies recedes that
f western medicines. CAM ractiti
ners are usu
a y vi age e ders and
ccuy a high  ace in the s
ciety. Their 
siti
n can b
e used t
increase the accetance
f m
dern medica ractices inc uding immunisa
ti
n am
ng the rura 
u ati
n. There sh
u d be greater integrati
n
f m
dern a
nd traditi
na medica systems which has been achieved t
arge extent in the fa
r eastern Asian c
untries.17 The medica sh
 was the c
mm
nest s
urce
f medici
nes. Medica sh
s are c
mm
n in b
th the urban and rura areas
f Nea and tra
ining
f the drug retai ers has been tried as an ar
ach t
imr
ving the qua i
ty
f medica care.18,19 The use
f CAM remedies was significant y higher am
ng
ers
ns ab
ve the

age
f 30 years and am
ng fami ies
f
w s
ci
ec
n
mic status. The use was a s

significant y higher am
ng rura h
useh
ds. S
ec
n
mic criteria, ack
f acce
ssibi ity t
m
dern hea th care systems and easy avai abi ity
f herba remedies
were the c
mm
n fact
rs redis
sing t
the use
f CAM remedies in Nea . Se ftreatment and h
me remedies are a c
mm
n and
ften necessary art
f hea th care
. The reas
ns c
mm
n y cited f
r se f-medicati
n were easy avai abi ity
f herbs
, revi
us exerience
f treating a simi ar i ness and ec
n
mic c
nstraints. Th
ese were simi ar t
the reas
ns cited in revi
us studies.11,19 Thirty nine fami
ies surveyed had used se f-medicati
n which is simi ar t
re
rts in the itera
ture.15,21 Ana gesics were the c
mm
nest drugs used f
r se f-medicati
n. Se fmed
icati
n was m
re c
mm
n am
ng rura h
useh
ds (z=3.2, <0.05) c
mared t
urban

nes. Drug h
arding has been re
rted in the iterature 14 and distance is an i
m
rtant fact
r inf uencing the uti isati
n
f hea th services.8 Because
f the
difficu ty in reaching hea th care services and because the medica sh
s are wi
de y distributed in the vi ages the rura 
u ati
n may be m
re r
ne f
r se f
-medicati
n ractices. Increased accessibi ity t
medicines, imr
vement
f the
g
vernment hea th care system and a greater integrati
n
f traditi
na and m
der
n hea th systems wi he  t
imr
ve the hea th status
f the 
u ati
n. Furth
er studies t
assess drug use atterns and hea th care needs
f the 
u ati
n a
re urgent y required. References: 1. Gart
u a RP. A ternative medicati
n racti
ces (dissertati
n). Darjee ing( India). Centre f
r Hima ayan Studies, N
rth Beng
a University, 1992. 2. Ni ss
n M, Trehn G, As und K. Use
f c
m ementary and
a ternative medicine remedies in Sweden. A 
u ati
n-based
ngitudina study w
ithin the n
rthern Sweden MONICA r
ject. J Int Med 2001;250(3):225-33. 3. Kess
er RC, Davis RB, F
ster DF, an R
may MI, Wa ters EE, Wi key SA et a . L
ng ter
m trends in the use
f c
m ementary and a ternative medica theraies in the Un
ited States. Ann Int Med 2001;250(3):262-8.

4. Mitzd
rf U, Beck K, H
rt
n-Hausknecht J, Weidenhammer W, Kindermann A, Takaes

M et a . Why d
atients seek treatment in h
sita s
f c
m ementary medicine.
J A tern C
m ement Med 1999;5(5):463-73. 5. Furnham A, Kirkca dy B. The hea th
be iefs and behavi
urs
f
rth
d
x and c
m ementary medicine c ients. Br J C i
n Psych
1996;35:49-61. 6. Shrestha R, Lediard M. Faith-hea ers: A f
rce f
r ch
ange. UNICEF, Kathmandu, 1980. 7. Sharma HB, Gautam RP, aidya S. (Eds.) Distric
t deve
ment r
fi e
f Nea . Inf
rma sect
r research and study center, Kathm
andu, 2001. 8. Dhunge B. Accessibi ity t
s
cia services in rura Nea : a cas
e study in Kavre district (dissertati
n). Bangk
k. Asian institute
f techn

gy
, 1983. 9. Chau agai CN. C
mmunity financing f
r essentia drugs in Nea . W
r d
Hea th F
rum 1995;16(1):92-4. Tab e 1: S
urces
f medicine s
ught by the res
n
dents during hea th enc
unters N
.
f enc
unters S
urce Medica sh
 Hea th 
st
Traditi
na ractiti
ners H
me remedies H
sita T
ta 61 41 32 24 6 164
Tab e 2: Number
f visits t
a c
m ementary medicine ractiti
ner acc
rding t

the age
f the atients
Age
f atient

 30 years System
f medicine M
dern C
m ementary T
ta 66 16 82

>30 years T
ta
52 30 82
118 46 164+
z va ue = 2.46, <0.05 + The 120 ers
ns wh
had been rescribed medicines in th
e 6 m
nth eri
d under eva uati
n had made mu ti e visits t
the ractiti
ners
Tab e 3: C
m ementary medicine use acc
rding t
the s
ci
ec
n
mic status
f the
fami y System
f medicine Average m
nth y inc
me (Rs.) <1000 1000-3000 >3000 T

ta M
dern 17 58 43 118 C
m ementary 19 , 12 15 46
T
ta
36 70 58 164+
z = 2.7, <0.05 c
mared t
the gr
u with average m
nth y inc
me greater than 3
000
z =4, <0.05 c
mared t
the gr
u with average m
nth y inc
me between 1000
and 3000 + The 120 ers
ns wh
had been rescribed medicines in the 6 m
nth eri

d under eva uati
n had made mu ti e visits t
the ractiti
ners . Tab e 4: Rur
a -urban differences in the frequency
f se f-medicati
n

Se f-medicati
n P ace
f residence Urban Rura T
ta

15 24 39 N
t used 58 15 76

z va ue =4.55, <0.05 Used

T
ta
73 39 112
REIEW
In Nea , traditi
na hea th care r
viders have an im
rtant r
e t
 ay in th
e r
visi
n
f hea th services. N
n-d
ct
r rescribing
f a
athic medicines i
s c
mm
n y carried
ut by c
m
unders, hea th assistants and
ther ractiti
ners
. Se f-treatment in which herba remedies  ay a arge r
e is a s
c
mm
n. M
st

f the revi
us studies have been carried
ut in the Kathmandu va ey. As studi
es in the P
khara va ey are acking the resent study was carried
ut. Meth
ds:
The study was carried
ut in P
khara sub-metr

itan city and the surr
unding
vi ages in the m
nth
f Setember 2001 using a semi-structured questi
nnaire by
the hea th w
rkers
f the c
mmunity medicine deartment. The attern
f drug us
e in the receding 6 m
nth eri
d was n
ted. The d
ct
r and the hea th assistant
were the c
mm
n y visited ractiti
ners. D
ct
rs in rivate ractice acc
unted
f
r 60.2 %
f the t
ta visits t
d
ct
rs. The uti isati
n
f g
vernment hea th
faci ities was
wer than that re
rted by revi
us studies in Ethi
ia and Thai
and. In a revi
us study in Nea rivate ractiti
ners were f
und t
be m
re 

u ar than the g
vernment hea th ers
nne The reas
ns cited f
r the reference
were the rivate ractiti
ners were
ca e
 e and were m
re accessib e at an
y time
f the day
r night. A r

rti
n
f the res
ndents had visited g
vernme
nt d
ct
rs as rivate atients when they were d
ing rivate ractice in the even
ings. CAM remedies c
ntinue t
be 
u ar b
th as h
me remedies and
n rescrit
i
n by a CAM ractiti
ner. Herba remedies as sh
wn in a revi
us study are easi
y avai ab e and in Nea kn
w edge
f herba remedies recedes that
f western
medicines. CAM ractiti
ners are usua y vi age e ders and
ccuy a high  ace
in the s
ciety. Their 
siti
n can be used t
increase the

accetance
f m
dern medica ractices inc uding immunisati
n am
ng the rura 

u ati
n. There sh
u d be greater integrati
n
f m
dern and traditi
na medica
systems which has been achieved t
arge extent in the far eastern Asian c
untri
es. The medica sh
 was the c
mm
nest s
urce
f medicines. Medica sh
s are c

mm
n in b
th the urban and rura areas
f Nea and training
f the drug retai e
rs has been tried as an ar
ach t
medica care. 2.REIEW OF LITERATURE: ALLOPA
THIC /S AYUREDA PRACTISES IN
TERTIARY CARE INSTITUTE URBAN NORTH INDIA. (THIS RESEARCH PAPER IS ATTACHED ALON
G WITH THIS FILE PLEASE SEE ADOBE READER FILE )
REIEW
This study c ear y indicated the 
u arity
f cr
ss-athy ractises am
ng b
th
qua ified a
athic and ayurvedic ractiti
ners. H
wever, c ause 1.13
f medica
c
unci
f India r
hibits the a
athic ractiti
ners fr
m a
athic system

f medicine. Hence, there is urgent need t
undertake educati
na and re
rienta
ti
n r
grammes
f registered medica ractiti
ner regarding vari
us MCI ru es a
nd regu ati
ns. Even the ayurvedic ractiti
ners need t
be adequate y trained t

rec
gnize c
nditi
ns that require referra s t
a
athic ractiti
ner. M
re
v
er arge sca e eidemi

gy studies sh
u d be c
nducted b
th in the urban and ru
ra art
f the c
untry, c
maring the trend
f cr
ss-athy ractises am
ng qua
ified ractiti
ner
f the b
th system
f medicines as we as c
maring the tren
d
f CAM and a
athic drugs use as se f medicati
n between different secti
ns

f the s
ciety . N
nethe ess, high qua ity, c inica trai s are required t
esta
b ish the safety and efficacy
f ayurvedic drugs . The benefit
f the atient i
es in the
tima ba ance and evidence based use
f the tw
systems and this nee
ds t
be enc
uraged esecia y in deve
ing c
untries ike INDIA with inadequat
e d
ct
r atient rati
.
CHAPTER-2
INTRODUCTION OF COMPANY

BRIEF PROFILE OF IND SWIFT GROUP Ind Swift Gr
u, a egendary f
rename in the w

r d C ass Pharmaceutica Industry wh
has br
aden its h
riz
ns by  ucking r
f

und & sark ing f

trints
n mu tifari
us diversified fr
nts, whi st g
ing stea
di y and sure y, scriting a success st
ry fi ed with enviab e mi est
nes and 
i
neering breakthr
ughs and has subsequent y emergent as a gr
u with an annua
turn
ver
f 1600 Cr
re. ORGANISATIONAL STRUCTURE-IND SWIFT GROUP Ind Swift gr
u
, as harmaceutica business m
de is
ne
f India's argest manufacturer
f hi
gh gr
wth mu ti segment harmaceutica finished d
sage f
rms and API's (Active P
harmaceutica Ingredients). Manufacturing
f Pharmaceutica finished d
sage are
carried
ut at 7 state-
f-the art manufacturing faci ities which are sec
nd t
t
he n
ne are du y certified and ar
ved by WHO GMP, sread
ver an area
f 12, 0
0, 000 sq. ft. with manufacturing caacities c
nfirming t
stringent TGA/MHRA a
r
va s; 
ssessing an insta ed caacities
f 3 bi i
n units c
mrising tab et
s, casu es, Ointments, Injectab e, Liquids & Dry Syru (a
atest f
rmu ati
ns
with a marketing netw
rk. API secti
n has sread
ver an area
f 7 Lac sq. ft,
carried
ut at 3 different state-
f-the-art units ar
ved by USFDA and E.U regu
at
ry auth
rities with a marketing netw
rk sread
ver in 40 c
untries viz. Eur

e/USA/Midd e East 
ssessing 2 atented m
ecu es with 11 m
ecu es in
ffing
It 
ssesses 50% ex
rts ercentage. Ind Swift entered int
bu k drugs with its

wn Research and Deve
ment faci ity and ab
rat
ries at Derabassi. Later
n, t
h
se units g
t USFDA ar
va and g
t the r
cess atents f
r C arithr
mycin f
r
US and a ied markets and further five m
re atent drugs await c earance f
r th
e m
ment. A j
int venture with Iran has a s
been signed f
r the manufacturing

f C arith
rmycin with c
nstructi
n underway and wi start
erati
ns by the end
2008. The c
many has
ffices and su ies harma drugs n
t
n y in India but

verseas as we .
R & D (Research & Deve
ment)

Ind Swift is kn
wn f
r it's reverse engineering abi ity with high y f
cused R &
D caabi ities (du y ar
ved by Deartment
f Science & Techn

gy, G
vt.
f In
dia) and is equied with state-
f-the-art equiment, faci ities and ta ented 



f scientists and Researchers. A we acceted exertise in NDDS, in India an
d the w
r d
ver. A US atent f
r C arie OD, with a market size
f US$ 300 mi i

n. An
ther atent f
r Fex
fenadine ODT with a market size
f US$ 2.5 bi i
n. D
eve
ment
f 10 new m
ecu es with a market size
f US$ 6 bi i
n. Ind Swift's
eff
rts and achievements in taste masking
f macr
ides was India's first.......
.. and remains the
n y feat
f its kind in the c
untry. The R &D deartment is
a s
inv
ved in creating internati
na

rtunities and a iances f
r CRAMS bu
siness, c
ntributing significant y t
the C
many's r
fitabi ity. It a s

ffer
s c
m ete su
rt t
internati
na artners f
r rearing and fi ing d
ssiers f

r finished d
sages. By taking giant strides
n r
ads ess trave ed, Ind-Swift h
as bec
me
ne
f India's fastest gr
wing harmaceutica c
manies.
R & D's Achievement
Its i
neering R & D eff
rts have ed t
the creati
n and intr
ducti
n
f b
ckb

wering dr
uster drugs ike: Atr
vastatin One
f the m
st effective ch
ester

ugs with an estimated market size
f US$ 12 bi i
n. Nitaz
xanide a w
nder,
ne

f its kind anti-diarrhea with a market
f US$ 6 bi i
n. Pi
g itaz
ne an antidiabetic drug ranked am
ng the first five in its Theraeutic segment. Arthri a
n herba w
nder f
r the treatment
f Arthritis. Anar
ct an ayurvedic r
duct r

viding re ief fr
m i es within 24 h
urs with n
a
athic c
metit
r. Ind-Swif
t has strategic R&D and manufacturing a iances with c
manies in the United Kin
gd
m, Turkey and Iran. In f
rmu ati
ns fr
nt, Ind Swift r
ud
f its mu tifari
u
s achievements viz. Neur
hen f
rte, a c
m
siti
n
f Ibur
fen & Acetamen
fen.
Ind Swift is the c
many t
give this c
m
siti
n t
the c
untry f
r the first t
ime. An
ther f
rmu ati
n i.e. Sur
x SR, a c
m
siti
n
f Is
xrine

He , sustained re ease tab ets was first time aunched in India in tab et f
rm.
M
uth diss
ving tab ets techn

gy was intr
duced f
r the first time in India b
y Ind Swift. The c
many t
day stands sec
nd in the n
rth in harmaceutica sect

r. It is an h
n
ur t
add here that we are am
ng the t
 500 f
rtune c
manies

f India and have been ranked at N
. 35 by IMS/ORG in Pharmaceutica industry &

ssess a 
rtf
i

f 650 r
ducts with resence in high gr
wth theraeutic seg
ments
f Cardi

gy, Diabet

gy, Anti deressant, anti-a ergic, Anti- infectiv
e, Neur

gy & Onc

gy with a nati
n wide distributi
n netw
rk c
mrising 1200
marketing r
fessi
na w
rking with 12 marketing divisi
ns, 50
ffices in India,
3000 suer st
ckists and st
ckists.
Sark ing f

tstes
n diversificati
n fr
nt are as under menti
ned:Infrastructu
res: Ind Swift has radianced u in infrastructures business in the name and sty
e
f Ind Swift Infrastructures and deve
ers Ltd, and has c
me u with a mu ti c
r
re r
ject named Rega ia T
wers,
f c
urse a s
ciety with 2 bedr

m /3 bedr

m f
ats and enth
uses
wing a mystique which is exem ary in itse f which n
t
n y
ref ects a diversified transf
rmative se t
infrastructures fr
nt but a uniq
ue state
f art with the best
f secificati
ns a s
. In infrastructures, Ind Sw
ift  ans t
be emergent with m
te s & Res
rts r
ject in the uc
ming hases.
Pub ishing & Packagings:
Ind Swift by virtue
f its str
ng business acumen has a s
ut a ste in the fie
d
f ub icati
ns a s
in the name and sty e
f Mansa Print & Pub ishers Ltd's
which has h
vered
ver the industry within a very sh
rt san by c
ming u with A
uminum Divisi
n in 2007 wherein the manufacturing & rinting
f vari
us tye
f
ackaging materia viz. A uminium c
asib e tubes, m
n
cart
ns etc is undert
aken and n
w wi add a new feather in ISL's ca by aunching a searate unit f

r PE, Lami tubes and PET b
tt es. N
t
n y this it further r

ses t
c
me u w
ith a stati
nary unit f
r which the bui ding has a ready been c
nstructed. The t

ta  an wi increase Mansa's sa e by 200%. An
ther r
ject f
r Injuncti
n m
u
ding has a s
been r

sed. B
th these  ants have a t
ta ay
ut  an
ut
f
Rs. 40 cr
re.
Media & Pub icati
n:

Ind Swift has f
cused u in media & ub icati
n sect
r under the name Ind Swift C

mmunicati
ns Pvt. Ltd with its i ustri
us and inf
mercia j
urna s as Pharmabuzz,
Trendz, ADI (Drug Index), Agr
vet and further r

ses t
c
me u with Genera ma
gazines
and tab
ids.
S
ftware Deve
ment:
Ind Swift has a s
entered int
IT & s
ftware with their initia r
jects
f dev
e
ing web 
rta s, search engines
timizati
ns, website deve
ment, s
ftware
& ERP systems deve
ment. Its initia 
rta s which are a ready
n air are OTC
mart.c
m, buysweeth
me.c
m, ainting &h
t
grahs.c
m, d
ct
rs
n ine.c
m & ayur
vedaherbs.c
m.
Sark ing f

tstes
n diversificati
n in Educati
n fr
nt are undermenti
ned:Swi
ft Institute:Our Swift Institute is exc usive y diverse fr
m the  ente
us riva
te educati
na instituti
ns cr
ing u in N
rth India, having w
r d c ass infra
structure, facu ty, ab
rat
ries and
ther faci ities. T
initiate with, we have
instituted six m
nths Industria Training C
urses in Pharmaceutica Sciences, f

r Oerat
r Leve Training which has enab ed the 10th
r 10+2 students t
start
a career in the b

ming Pharma industry & unti n
w we have a ready trained and
 aced m
re than 400 students at Ind Swift which we fee c
ntributes a
t t
th
e ski ed man
wer starving industry. Swift Fundamenta Research Educati
n : SFR
E (Swift Fundamenta Research Educati
n ) is a s
ciety made under the banner
f
Ind Swift which has recent y aid an an
ther ste
n the diversificati
n sree a
nd has f
rayed u with a Pharmacy c
ege at Rajura with the name & sty e
f Swi
ft Sch


f Pharmacy, and is a unique state
f art with the best
f secificati

ns a s
. With this new venture
f IND SWIFT, we have been ranked as the i
neers
in this art
f the c
untry having a s
id harmaceutica industria backgr
und
t
c
me u with
ur
wn

Pharmacy & Nursing institute. The institute wi be
erati
na fr
m current ses
si
n year 20082009 with an intake
f 60 students in the fie d
f Pharmacy and Nu
rsing each, in the first year by virtue
f its high res
urcefu ness and kn
w-h
w
r
vide qua ity educati
n t

ne and a , asiring careers in the fie
and wi
d
f Pharmacy. We manifest t
be imminent with Engineering, Architecture, Manage
ment, H
te Management, Genera Management, Sch

s
f Dentistry, Ayurveda Physi

theray and Medica Techn

gy and fina y a Medica C
ege with its functi
ni
ng
erati
na by 2010-11 under the budget
f Rs. 250 Cr
re with a secific targ
et
n Medica T
urism. D
mestic Marketing: The c
many's new divisi
n diagn
sis de
a ing in medica equiments & devices thereby f
cusing ers
na hea th care was
aunched in December 2007 and has ref ected r
mising erf
rmance & is gr
wing
eas and b
unds fr
m the first m
nth
f its aunch which has given utm
st c
nfid
ence t
the c
many t
get the aggrandized sa es and c
ntributi
n n
t in the cur
rent year but in the f
rthc
ming years as we . N
t
n y this, the divisi
n r
j
ects t
achieve a business
bjective
f 10 cr
res with imressive c
ntributi
n t

ISL and 
ssesses a strategy
f adding u few
ther secia ty r
ducts in the
existing range
f ers
na hea th care & Academic B
dy m
de series. An
ther div
isi
n aunched by y
ur c
many is Anima Hea th Care which is an abs
ute y new c

ncet with
uts
urced marketing and has r
ved
ut t
be an individua r
fit ce
nter. Aart fr
m strugg ing uhi
f
r the current range
f r
ducts
ur Ethica
marketing have intr
duced th
se r
ducts during the year which are m
n

istic
in nature viz. Cirrh
iv which has r
ved
ut t
be a remedy in Heatitis and

ther iver dis
rders. Other brands intr
duced by y
ur c
many during the year ar
e T
c av 625, Emtee 25 and Timc
Eye Dr
s. In Generics, y
ur c
many emerged
as the 2nd rank Pharma Generic c
many and has attained the fame
f featuring it
s few brands (Amyc
x, Swim
x, Ox
, Swif
x and Cafz
ne (a ready achieving the s
a es gr
wth
ver 25 cr
re) as the t
 brands in Generics. C
many's brand Swim
x
has been en isted am
ng eading brands in ORG IMS and Amyc
x eads the que am

ng t
 300 brands
f the industry. Annua gr
wth f
r the c
many during the year
is 36.73%.
RESEARCH & DEELOPMENT

L

king at the current scenari
where the harmaceutica maj
rs are engaged in t
he advancement
f R & D, we have been c
metent en
ugh t
w
rk
ut
n n
n infrin
ging r
cesses, N
ve Drug De ivery Systems, d
ssiers, stabi ity data r
fi ing,
c
ncetua izati
n
f new m
ecu es (and theref
re a nmber
f r
duct c
mbinati

n have been deve
ed and are ready t
be aunched by
ur marketing divisi
ns).
Y
ur c
many's R&D is inv
ved in creating internati
na

rtunities and a ia
nces f
r CRAMS (secia y c
ntract Research) t
make it c
ntribute 30%
f r
fit
s. Ti date tw
maj
r c
ntracts were signed an have been de ivered. We are h
e
fu t
attain m
re c
ntracts
n r
duct deve
ment and stabi ity data r
fi ing
. Aart fr
m this, we are a ying invincib e eff
rts t
get ar
va s f
r a Bi

-equiva ence centre which wi further strengthen the basket
f R&D. T
strength
en the CRAMS business t
the exquisite eve , y
ur c
many is tying u with vari

us academic institutes. By virtue
f the hard endeav
rs
f R&D a thr
ugh the
year, unique c
mbinati
ns/NDDS
f sing e m
ecu e are ar
und the c
rner and awai
ting aunch by this year. Aart fr
m this, R&D is emhasizing
n a maj
r area wh
ich is c
st Reducti
n. M
re than 5%
f t
ta revenues have been  anned t
send

n the c
many's R&D and the same wi be c
ntinued in the f
rthc
ming years as
we . Units
f IndSwift: IndSwift has tw
units in PARWANOO and tw
in BADDI.
Missi
n:

isi
n:

Ind Swift Ltd. M
ving t
wards INR - 1000Cr. by 2010

a ues
1.C
nsistent Pr
fitab e Perf
rmance 2. C
mmitment t
maximize the wea th
f
ur
shareh
ders and catering t
the interests
f
ur cust
mers and em
yees. 3. In
n
vati
n t
Nurture G

d Partnershis with Cust
mers 4. Deve
 theraies and r

cesses and r
vide services
f the highest va ue t
nurture g

d artnershis w
ith cust
mers 5. Res
nsibi ity t
wards Envir
nment, Safety and Hea th 6.Nurturi
ng the undying sirit f
r researching active substances t
c
mbat disease, r
te
ct the envir
nments we inhabit, and the S
ciety we serve. 7.C
mmitment t
the Hi
ghest Standards
f Ethics & Integrity 8.Acti
ns in acc
rdance with w
rds and va
ues. Resecting the aws in business ethics
f the c
untries in which we
erate
. 9.a uing the Abi ity t
Exce , Integrity, Kn
w edge, Ski , Diversity and Tea
m w
rk
f Em
yees 10.Treat every
ne fair y and with resect t
create an envir

nment
f Mutua resect, enc
uragement and teamw
rk.
Future and hist
ry:
In t
days world of rapid change, future shock is no longer shocking. To those who
do not plan for future, future may come too soon. But to those with careful pre
paration and accurate anticipation, to those with vision, future is where we are
going to prosper. Towards which desirable end, we endeavour today. With promisi
ng molecules in our manufacturing pipeline, we are going to meet our future with
great preparation and nonchalance.

For details visit our group companys website Indswift Labs Limited. To develop va
rious types of NDDS for selected therapeutic segments. 12 new drug / combination
being developed under NDDS to be introduced first time in India. Contract resea
rch Contract manufacturing Joint ventures in marketing finished dosage forms in
India, SAARC and South East Asian countries. - Dedicated to be an integrated hea
lthcare company: - Chain of Multi -specialty hospitals - Pharmacy chain - Chain
of diagnostic laboratories CHRONICLE: 2007-2008 Company has achieved the 35th ra
nk among top 300 pharma industries in 2007-08 Company has got international appr
ovals viz. MHRA(UK),TGA(Australia),WHO(Geneva) and other such regularly bodies.
We achieved MoH(UAE),TFDA(Tanzania),NDA(Uganda) and DACA(Ethiopia). The company
s new division Diagnozis dealing in medical equipments and devices was launched
in December 2007. Animal Health Care is another division launched by our company
which is absolutely new concept with outsourced marketing. Ethical marketing Di
vision of the company introduced products during the year viz. Cirrholiv useful
in curing Hepatities and other liver disorders. In Generics,company merged as th
e 2nd rank Pharma Generic Company New brands in Generic are Amyclox,Swimox,Oxo,S
wiflox and Cafzone achieving the sales growth over 25 crore. Companys manufactu
ring unit at Parwanoo has also been upgraded as per WHO standards. Companys Glo
bal Business unit (GBU) at Derabassi has got MHRA & TGA approval. Manufacturing
unit at Baddi(H.P.) received WHO GMP certification for tablet/SVP/Liquid manufac
turing. 2006-2007

Company has entered in an advanced stage of Launching its products in the Intern
ational Markets. The Companys 100% Export Oriented Global Business Unit,(GBU) i
s complaint to the GMP specifications of MHRA(UK),TGA(Australia) and other regul
atory bodies. Company also launched its product in Kenya and Senegal. The Compan
y has filled more than 100 dossiers for registration in about 20 countries aroun
d the world stretching from South America to Philippines. The third new division
is Agile which has been launched in joint venture with a Dubai based Pharma com
pany focusing on Pain Management & Anti-infectives. The Company introduced vario
us new product ranges in the domestic markets through its 12 marketing divisions
,a total of 40 offices in India,3000 stockists & superstockists across the count
ry with an enhanced field force of 1400 marketing professionals endeavoring hard
in broaden therapeutic segments of Cardiology,Diabetology,Neurology and Oncolog
y. Company has been ranked 41st among top 50 leading pharmaceutical giants. Comp
any R&D with available scientific pool of 100 scientists working on different pr
ojects on dossiers,DMFS in CTD formats,stability data profile,conceptualization
of new molecules,planning for bioequivalence and clinicals. More than 5% of tota
l revenues have been planned to spend on the companys R&D . Companys another f
eather in its cap is its new manufacturing facility for soft gelatin encapsulati
on with an annual capacity of 35 Crore Soft gelatin Capsules, which will be put
into operation during current financial year. 2004-2005 Launched combination of
Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia.
Ind Swift Group achieved a turnover of 480 crores. 2004 Launched Mukur Division
with focus on ophthalmology, neuropsychiatry and ENT. Another division launched
by the name Resurgence catering to the Anesthesiology and Oncology segments. Ind
-Swift group achieved a turnover of INR 375 Crores. Launched Nitazoxanide, an an
tidiarrhoeal drug, first time in India after successful clinical trials.

Got DGQA registration Opened first overseas office in New Jersey, USA 2003 Ind-S
wift group achieved a turnover of INR 300 Crores Launched another division by th
e name Ind-Swift Biosciences. Ind-Swift enters into formulations export to 6 cou
ntries. Filed Patent in US for Clarithromycin 2002 Bagged ISO 9001-2000 Certific
ation. Attained leading position in the world in the products like Clarithromyci
n granules Exports to almost 40 countries in the world and set up eleven represe
ntative offices worldwide. 2001 Launch of Institution/Hospital Division. 2nd Com
pany to launch Pioglitazone and Candesartan in India 2000 Launched Super Special
ty Division (SSD) focusing on Cardiology and Diabetology segments. 1997 A 30 cro
re multipurpose plant commissioned with five independent blocks erected as per c
GMP and US FDA standards, designed by Quara, Switzerland. Another Marketing Divi
sion launched with the name Ind-Swift Health Care. 1996 Ind-Swift floated Ind-Sw
ift Laboratories Limited in 1995 to initiate a backward integration into the man
ufacturing of APIs and advanced intermediates. 1994 Ind-Swift went public with i
ssues oversubscribed 52 times 1991 Set up a manufacturing facility for injectabl
es and eye/ear drops. 1986 Birth of Ind-Swift limited. Introduced for the first
time in India sustained release tablet of Isoxsuprine HCL 1983

Year of Foundation
MARKETING:

1000 professionals in different divisions market finished dosage forms throughou
t the Over 40 offices in India Eleven representative Offices worldwide. Strong d
octors base of over 2.5 lakh doctors of various specialties. Strong retailer cov
erage base of over 3 lakh retailers. Stockists base of over 3000 all over India
country.
MANUFACTURING:

All the manufacturing units are designed to comply with current GMP norms as pro
posed
by stringest world regulatory bodies like USFDA, MHRA, EU, and WHO, and accredit
ations from ISO 14000 Ind-Swift is known as one of the biggest global bulk produ
cers of APIs like clarithromycin, fexofenadine, atorvastatin etc. (For details v
isit our group companys website Ind-Swift Labs Limited.) trials Launched combinat
ion of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, Launched Nita
zoxanide, an antidiarrhoeal drug, first time in India after successful clinical
first time in Asia

QUICK FINANCIAL SYNOPSIS:

BRIEF: For the fiscal year ended 31 March 2009, IND Swift Ltds revenues increas
ed 14% to RS5.92B. Net income increased 1% to RS314.5M. Revenues reflect an incr
ease in income from operations. Net income was partially offset by an increase i
n consumption of raw materials, higher purchase of traded goods, an increase in
employee cost, higher depreciation & amortisation expenses and lower other incom
e. Price Performance Period 4 Week 13 Week 26 Week 52 Week YTD Price History Per
iod 12 Month High 12 Month Low Current P/E
Balance sheet
Mar  08 Mar  07 Mar  06 Mar  05 Mar  04
Actual (%) 4.90 32.49 61.64 -13.77 53.93 Value 26.80 10.50 2.41
Sources of funds
Owners fund

Mar  08 Equity share capital Share application money Preference share capital R
eserves & surplus 7.44 0.16 170.62
Mar  07 7.44 0.16 141.17
Mar  06 7.44 2.95 119.34
Mar  05 7.28 3.10 102.52
Mar  04 4.63 6.04 65.74
Loan funds
Secured loans Unsecured loans Total 308.91 83.00 570.12 227.50 74.80 451.07 153.
09 40.58 323.39 90.36 27.08 230.33 49.63 18.02 144.06
Uses of funds
Fixed assets Gross block Less : revaluation reserve Less : accumulated depreciat
ion Net block Capital work-in-progress Investments 159.34 18.12 141.22 97.49 28.
30 96.99 12.07 84.92 98.75 18.76 50.80 8.28 42.52 88.85 15.39 32.23 6.20 26.03 2
2.88 18.67 23.90 4.88 19.02 4.70 14.75
Net current assets
Current assets, loans & advances Less : current liabilities & provisions Total n
et current assets Miscellaneous expenses not written Total 425.04 147.18 277.86
25.25 570.12 330.58 106.94 223.65 24.99 451.07 218.45 60.33 158.12 18.51 323.39
192.76 41.22 151.54 11.22 230.33 137.36 37.54 99.82 5.76 144.06
Notes:
Book value of unquoted investments Market value of quoted investments Contingent
liabilities Number of equity sharesoutstanding (Lacs) 5.39 19.38 371.78 371.78
5.27 52.54 43.87 371.78 4.61 87.90 54.50 72.76 2.08 83.42 46.25
Market Capitalisation Market Cap (Rs Millions) Shares Outstanding Float Per Shar
e Data (Rs INR) Earnings Sales 8.45 159.26 756.58 37.18 23.50

Book Value Cash Flow Cash Valuation Ratios Price/Earnings Price/Sales Price/Book
Price/Cash Flow Return on Equity Return on Assets Return on Investment
---2.41 0.13 -1.86 ---26.40 6.68 5.31 ------Management Effectiveness (%)
Profitability Ratios (%) Gross Margin Operating Margin Net Profit Margin Dividen
d Information Dividend Yield (%) Payout Ratio Financial Strength Quick Ratio Cur
rent Ratio LT Debt/Equity Total Debt/Equity Dividend Per Share (Rs INR) 0.0
Chart for indswift(stock exchange)

PRODUCT RANGE AND LAUNCH:

Product Netazox Clarie OD Glitter Candez Atstat UT Guard Fexidine Excef Clarie D
T Clarie Suprox SR Anin
Therapeutic Anti diarrhea Macrolide Anti diabetic
Position at the time of launch in India 1st 2nd 5th 2nd 4th 2nd 3rd 3rd 1st 2nd
2nd 2nd
Year ofLaunch 2004 2003 2001 2001 2000 2000 2000 1999 1999 1998 1987 1985
Cadiovascular Cardiovascular Vasodilator Anti histamine Antibiotic Macrolide Mac
rolide Vasodilator Allyoestrenol
Product Range of the Ethical Division of Ind - Swift INJ ANIN-250 INJ ANIN-500


INJ DECANEUROPHEN-25 INJ DECANEUROPHEN-50 INJ NEUROPHEN-25 INJ UTGARD(5 ML) INJ.
UTGARD (1 ML) INJ. VORANIN-100 INJ. VORANIN-200 INJ INORINE 2 ML TAB ANIN TAB C
LARIE - 250 TAB CLARIE - OD TAB CLARIE DT TAB COZY PLUS TAB ETOXIN - B TAB NEURO
SPAS CD TAB SUPROX TAB SUPROX SR TAB STEMIN TAB STEMIN FORTE TAB. INDAXIN -B6 TA
B. INDCEF-DT TAB. INDCEF-100 TAB. INDCEF-200 TAB. UTGARD TAB GLUFIT-15 TAB GLUFI
T-30 TAB.MENOGUARD TAB.NEUROSPAS-MF TAB TOPCLAV-625 TOPCLAV D/SYRUP TAB TOPCLAV375


TAB INORINE TAB INORINE-M TAB TERPREG 200 MG TAB EMTEE TAB ERGEST - LD TAB ERGES
T TAB FERTILIN-50 TAB MEDANIN-10 MG TAB CALSTAT TAB CALSTAT-DS TAB OFREE CAP NEU
ROPHEN FORTE CAP NEUROSPAS CAP DISTONE CAP BENPROST-8 CAP VORANIN-100 CAP. VORAN
IN-200 CAP MUBEXIN CAP. ANAPROCT CAP INDILAC CAP. CIRRHOLIV CAP CALSTAT-BD CAP P
M CARE COZY KID ETOXIN-B EXPECTORANT PHENA KID PHENA P OLIADE BATH OIL COZY COOL
DROPS NEUROSPAS-DROPS DISTONE SYRUP


CALSTAT-SUSP UTININ SYP STEMIN-GM STEMIN-MF ANAPROCT OINTMENT MUBEXIN ZINC DROPS
INDCEF-LB DRY SYRUP GDSAFE DRY SYRUP GDSAFE-DS DRY SYRUP SYP. AMBICET INDILAC S
ACHET
Ayurvedic products:


Proven Ayurvedic remedy for cardiovascular ailments Helps in maintaining optimal
blood pressure Lowers blood cholestrol Useful aid for liver ailments

Helps in controlling DIABETES Mellitus Helps maintaining appropriate Blood Sugar
Level Important in Comprehensive Diabetic Care

Works as Anti Stress (Adaptogen) Works as Anti Oxidant Restores and enhances Phy
sical & Mental Endurence Useful in Respiratory system ailments

Improves quality of semen Improves Sperm Count and motility. Effective in Impote
ncy Improves nourishment to body tissues Promotes urinary flow

Optimize Gastrointestinal Function Natural and gentle Laxative useful in constip
ation Effective in Heartburn and stomach upset Useful in Chronic Diarrhoea and P
iles Combines well with Amalakiy

As Lipid Regulator, Alters Lipid Metabolism Promotes good cholestrol Lowers bad
cholestrol Lowers triglyceride and Effective in maintaining healthy Cardiovascul
ar system.

Excellent Blood Purifying properties Natural aid for Skin diseases Bitter taste
helps in worm infestations and viral infection Effective in Diabetic care

Board and directors and staff:

Mr. S. R. Mehta Mr. N.R.Munjal Dr. G. Munjal Dr. V. R. Mehta Mr. Himanshu Jain M
r. V. K. Mehta Mrs. Nirmal Agarwal Mr. K.M.S.Nambiar Dr. N.D.Aggarwal Dr. R.S.Be
di Dr. H.P.S.Chawla Dr. S.K.Mathur Mr. N.K.Bansal Mr. Amit Tarafder Mr. R.K.Sood
Mr. O.P.Thapliyal Mr. Gaurav Aggarwal Mr.Anurag Kastwar Mr.J.S. Saini Chairman
Vice Chairman Managing Director & CEO Jt.Managing Director Executive Director Di
rector Director Director Director Director Director Director Group Head(Finance)
Vice President(Finance) Company Secretary vice president (HR) vice president (c
ommercial) vice president (marketing) senior manager( marketing)
CHAPTER- 3

OBJECTIVE OF THE STUDY:

1> To assess the usage of allopathic or ayurveda system by the doctors. 2> To st
udy the preferences of the systems by the doctors taking the reasons as side eff
ects, time duration , safety. 3> To study the availability the medicines in clin
ic or nearby retailers . 4> To know diversifying allopathic to ayurveda by indus
tries is right step or not. 5> To study the order of preferences by the doctors
towards the different medical professionals. SCOPE OF THE STUDY: The scope of st
udy means the subject matter to be researched in the study . it defines the over
all rationale of the study by explaining the geographically area of the study al
ong with type of the data. In order to accomplish the objectives of the project
. survey conducted in himachal Pradesh and Chandigarh to fill the questionnaire
by the doctors which designed for the purpose of the survey . on the basis of da
ta collected I analysis the result of the project .
RESEARCH METHODOLOGY
In order to gets information by various reasons the research methodology is as f
ollows: DATA COLLECTION: Adequate and authentic data is the foundation stone for
an analysis. It is very necessary that the data should be adequate and relevant
so that the analysis which we derive from that data is exact. So data collectio
n requires due attention and care. In order to get the required basic informatio
n about the usage of medical system by doctors and for what disease . I relied o
n both primary data and secondary data. PRIMARY DATA:

Regular visit to the organization i.e.IndSwift Ltd. In Chandigarh and after regu
lar visit to market and meetings with doctors was made to obtain the required in
formation and learn about the market and organisation how it works. Interviews w
ith the management officials and staff of the organization to get latest informat
ion. SECONDARY DATA: Books, Magazines, Articles from internet etc. constitute th
e secondary sources of information for the project report. SAMPLING PLAN: Univer
se : The population of study consists of hamirpur and chandigarh. Sample Size :
Sample Sizes 40 respondants. 20 doctors of ayurveda and 20 from allopathic . Sam
pling Technique : I have used technique of convenience sampling. Geographical sc
ope: hamirpur (h.p) and chandigarh . . Tool for data analysis : Percentage metho
d for getting results. doctors and retailers (pharmacy shops) I
AN OUTCOME OF RESEARCH METHODOLOGY
Collection of Information from IndSwift.
Taking permission from guide.
Getting questionnaire filled from people

Analysis of information
Interpretation of data
Suggestion and Recommendations

CHAPTER-4
Evaluation study to assess the usage of Allopathic and ayurvedic system BY docto
rs (VIEWS OF AYURVEDA DOCTORS) NAME: QUALIFICATION DATE : .........
DO YOU USE ALLOPATHIC PRODUCTS? a. YES b. C. NO AT TIMES

Q.NO:2: NAME OF THE DISEASE FOR WHICH YOU PREFER ALLOPATHIC TREATMENT a. GIT b.
LIVER DISORDER c. HEART DISEASE d. CANCER e. ANY OTHER (PLEASE SPECIFY). .
NO RESULT % 20 Q.NO:3: (A) DOES PATIENT OVERALL SATISFIED WITH ALLOPATHIC PRESCR
IPTION AND MEDICINE GIVEN BY YOU? a. YES b. NO

(B) IF NO, WHAT IS THE COMPLIANCE OF PATIENT FOR ACCEPTANCE OF ALLOPATHIC TREATM
ENT .. .
NO RESULT % 20 Q.NO:4: YOUR PREFRENCE TO ALLOPATHY IS THEIR SHORT DURATION OF TR
EATMENT AS COMPARE TO AYURVEDIC a. STRONGLY AGREE b. AGREE c. NEUTRAL d. DISAGRE
E e. STRONGLY DISAGREE
NO RESULT % 20 Q.NO:5: (A) WHETHER MEDICINES ARE GENERALLY AVAILABLE WITH NEAR B
Y RETAILERS a. YES b. NO

(B) IF NO, WHAT IS REASONS FOR NON PROVIDING MEDICINES TO PATIENTS .............
................................................................................
...........................................
. NO RESULT % 20 Q.NO:6: DO YOU BELIEVE IN COMBINATION THERAPY (ALLOPATHY WITH A
YURVEDA) ? a. YES b.NO c. AT TIMES
NO RESULT % 5 Q.NO:7: WHAT IS THE TIME DURATION YOU PREFER FOR ALLOPATHIC TREATM
ENT? a. 3 DAYS b.3-5 DAYS c. A WEEK d.MORE THAN A WEEK

Q.NO:8: IN NEW ERA OF MEDICINE, COMPANIES ARE DIVERSIFYING FROM ALLOPATHIC PRODU
CTS TO AYURVEDA. DO YOU THINK THIS IS THE RIGHT STEP? a. YES b. NO PLEASE COMMEN
T ON YOUR ANSWER .
Q.NO:9: DO THE PATIENT SHOWS THEIR PREFERENCE TO ALLOPATHIC SYSTEM a. YES b. NO

Q.NO: 10: WHAT IS YOUR ORDER OF PREFERENCES IN RESPECT OF VARIOUS SYSTEMS OF MED
ICINES LIKE HOMEOPATHIC , ALLOPATHIC , AYURVEDA , UNANI. a. 1ST b. 2ND
K TO ALLOPATHIC

Evaluation study to assess the usage of Allopathic and ayurvedic system BY docto
rs (VIEWS OF ALLOPATHY DOCTORS) NAME: DATE :...................................
N:
Q.NO: 1: DO YOU USE AYURVEDIC PRODUCTS? a.YES b.NO c.AT TIMES
Q.NO:2: NAME OF THE DISEASE FOR WHICH YOU PREFER AYURVEDIC TREATMENT a. GIT

b.LIVER DISORDER c.HEART DISEASE d.CANCER

e.ANY OTHER (PLEASE SPECIFY). .

Q.NO:3: (A) DOES PATIENT OVERALL SATISFIED WITH AYURVEDIC PRESCRIPTION AND MEDIC
INE GIVEN BY YOU? a. YES b. NO (B) IF NO, WHAT IS THE COMPLIANCE OF PATIENT FOR
ACCEPTANCE OF AYURVEDIC .. .
Q.NO:4: THE REASONS FOR PREFERENCE OF AYURVEDIC MEDICINE, IS THEIR SAFETY AND NO
SIDE EFFECTS . a. STRONGLY AGREEE b.AGREE c.NEUTRAL

d.DISAGREE e. STRONGLY DISAGREE

Q.NO:5: (A) WHETHER MEDICINES ARE GENERALLY AVAILABLE WITH NEAR BY RETAILERS a.
YES b. NO (B) IF NO, WHAT IS REASONS FOR NON PROVIDING MEDICINES TO PATIENTS
. Q.NO:6: DO YOU BELIEVE IN COMBINATION THERAPY (ALLOPATHY WITH AYURVEDA) ? a. Y
ES b.NO c.AT TIMES

Q.NO:7: WHAT IS THE TIME DURATION YOU PREFER FOR AYURVEDIC TREATMENT? a. A WEEK
b.A MONTH c.SIX MONTHS d. MORE THAN SIX MONTHS
Q.NO:8: IN NEW ERA OF MEDICINE, COMPANIES ARE DIVERSIFYING FROM ALLOPATHIC PRODU
CTS TO AYURVEDA. DO YOU THINK THIS IS THE RIGHT STEP? a. YES b. NO PLEASE COMMEN
T ON YOUR ANSWER

Q.NO:9: DO THE PATIENT SHOWS THEIR PREFERENCE TO AYURVEDIC SYSTEM? a. YES b. NO

Q.NO: 10: WHT IS YOUR ORDER OF PREFERENCES IN RESPECT OF VARIOUS SYSTEMS OF MEDI
CINES LIKE HOMEOPATHIC , ALLOPATHIC , AYURVEDA , UNANI. a. 1ST b.2ND
CHAPTER-5 SUMMARY
This study is based on the usage of two medical system by the different doctors
. in this whole project the result was carried out by fillong the questionnaire
from the doctors of allopathic and

ayurvedic system. This study helps in to find out that which system is still sui
table for the chronic disease. Through this customer preference toward which sys
tem has been studied. This study also shows the doctors preferences towards the
combination therapy and market research from which , get the views of doctors on
the diversifying system from allopathic to ayurveda. Questionnaire is totally b
ased on straight answer from which we get the result fast and it become easy to
find the appropriate views of doctors on the subject of study. The analysis lead
s to conclusion.
CONCLUSION
In my market survey I found weightage towards the allopathic products . 35% of a
llopathy doctors use ayurveda medicine in prescription but in case of ayurvedic
doctors 80% of them , they are using allopathic medicine in prescription. I also
find that the combination therapy made by doctors doing great job in healing th
e disease like coronary heart disease , cancer and many more chronicle diseases.
As allopathic is first preference by the doctors but ayurveda is upcoming one.
Allopathy and ayurveda are as different as day and night, and hence the two sets
of opposing views. However, if one has to compare ayurveda and allopathy on one
platform, then such comparison might be a tad difficult. "Allopathy treats indi
viduals as an independent physical entity like a machine. It is further sub-divi
ded into various organs and systems looked after by different specialties. Where
as, ayurveda treats the individual as a whole, considering him to be a part of t
he universal whole. A positive aspect in the whole ayurveda vs allopathy issue,
is the fact that, people are now open to know more about this ancient science. A
lso while there might not be prejudices or bias against the same, there are cert
ain misconceptions, which can only be dispelled with knowledge and information d
issemination. "There are no prejudices surrounding ayurveda. There may be miscon
ceptions regarding its practice. If anything, the interest in this system of med
icine has been growing rapidly both in the domestic and international market, at
testing to its popularity and widespread acceptance . RECOMMENDATION:

According to findings that in current scenario doctors and patient move towards
the ayurveda but allopathic still rules. I would like to recommend IndSwift 1. D
octors have yet to find a solution for conditions like cancer pain and chronic p
ancreatitis in complementary therapies where modern interventional pain procedur
es are very effective. So herbal drugs use in cancer and heart disease is going
to be popular for the doctors. This finding helps IndSwift to capture market by
manufacturing of anti cancer herbal drug. 2. My findings helps IndSwift that it
should work on herbal medicines but along with allopathic. 3. In future company
get benefit if they prepare combination therapy medicines with no side effect an
d try to be 100% cure guarantee.
QUESTIONNAIRE: QUESTIONNAIRES ARE ATTACHED WITH THIS FILE NAMED AS QUESTIONNAIRE
01 QUESTIONNAIRE 02 BIBLIOGRAPHY: Amare G, Gedif T, Alemayehu T, Tesfahun B. Pa
ttern of drug use in Addis Ababa community. East Afr Med J 1997;74(6):362-7. Adj
ei DO, Arhinful DK. Effect of training on the clinical management of malaria by
medical assistants in Ghana. Soc Sci Med 1996;42(8):1169-76. Brians Klaas and Th
omas W. Gainey (1999).study of Determinants of disciplinary system effectiveness
. Journal of Economy and Society (1999). D.R. Cooper and P.S.Schindler, Business
Research Methods 9, (2006), pp. 505 Kessler RC, Davis RB, Foster DF, Van Rompay
MI, Walters EE, Wilkey SA et al. Long term trends in the use of complementary a
nd alternative medical therapies in the United States. Ann Int Med 2001;250(3):2
62-8.


Mitzdorf U, Beck K, Horton-Hausknecht J, Weidenhammer W, Kindermann A, Takaes M
et al. Why do patients seek treatment in hospitals of complementary medicine. J
Altern Complement Med 1999;5(5):463-73.

Nilsson M, Trehn G, Asplund K. Use of complementary and alternative medicine rem

edies in Sweden. A population-based longitudinal study within the northern Swede
n MONICA project. J Int Med 2001;250(3):225-33

Wexler-Morrison NE. Plural medicine in Srilanka:Do Ayurvedic and Allopathic prac
tice differs? Soc Sci Med 1988;27:531-44 WEBSITES: http://www.extensor.co.uk/art
icles/medicalsystem.html http://www.allbusiness.com http://www.extensor.co.uk/ar
ticle_archive.php http://www.managementparadise.com http://www.google.co.in http
://www.indswift.com http://www.researharticles.com/articlesmedicalveiws.html